Veterinary medicines European public assessment report (EPAR): SevoFlo, sevoflurane, Status: Authorised
English (EN) (81.94 KB - PDF) First published: 14/08/2007Last updated: 28/06/2024
English (EN) (81.94 KB - PDF) First published: 14/08/2007Last updated: 28/06/2024
On 27 June 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Imfinzi. The marketing authorisation holder for this medicinal …
On 27 June 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Lynparza. The marketing authorisation holder for this …
On 27 June 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Cresemba. The marketing authorisation holder for this …
Agenda of the CVMP meeting 21-23 May 2024 DraftReference Number: EMA/237161/2024
At the time of designation, pulmonary arterial hypertension affected approximately 1.4 in 10,000 people in the European Union (EU). This was equivalent to a total of around 73,000 people1, and is below the ceiling for orphan designation, which is 5 people …
Overview This medicine was designated as an orphan medicine for the treatment of diffuse large B-cell lymphoma in the European Union on 18 July 2022. This means that the developer will receive scientific and regulatory support from EMA to advance their …
Overview This medicine was designated as an orphan medicine for the treatment of follicular lymphoma in the European Union on 18 July 2022. This means that the developer will receive scientific and regulatory support from EMA to advance their medicine to …
On 27 June 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Balversa, intended for the treatment of urothelial carcinoma harbouring …
On 27 June 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Enzalutamide Viatris, intended for the treatment of prostate cancer. The …
On 27 June 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Eurneffy, intended for emergency treatment of allergic reactions ( …
On 27 June 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product mResvia, intended for the prevention of lower respiratory tract (LRT) …
On 27 June 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Nilotinib Accord, intended for the treatment of chronic myelogenous …
On 27 June 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a conditional1marketing authorisation for the medicinal product Ordspono2, intended for the treatment of follicular lymphoma …
On 27 June 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Piasky, intended as monotherapy for the treatment of adult and …
On 27 June 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Winrevair2, intended for the treatment of pulmonary arterial …
On 27 June 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Pegasys. The marketing authorisation holder for this medicinal …
Based on the review of the data and the company's response the Agency's questions, at the time of the withdrawal, concerns remained on the presence of nitrosamine impurities in the medicine and its provisional opinion was that Dabigatran etexilate …
On 27 June 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Infanrix hexa. The marketing authorisation holder for this …
On 27 June 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Xalkori. The marketing authorisation holder for this medicinal …